West Pharmaceutical Services (WST) Expected to Announce Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) is anticipated to release its earnings data before the market opens on Thursday, February 13th. Analysts expect West Pharmaceutical Services to post earnings of $1.71 per share and revenue of $740.87 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

West Pharmaceutical Services Price Performance

West Pharmaceutical Services stock opened at $324.25 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.23 and a current ratio of 3.00. The company has a market capitalization of $23.48 billion, a price-to-earnings ratio of 48.11, a price-to-earnings-growth ratio of 19.31 and a beta of 1.01. West Pharmaceutical Services has a 1 year low of $265.00 and a 1 year high of $409.72. The company’s 50 day simple moving average is $332.34 and its 200-day simple moving average is $314.81.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 11th. Stockholders of record on Friday, February 7th will be given a dividend of $0.21 per share. The ex-dividend date of this dividend is Friday, February 7th. This represents a $0.84 annualized dividend and a dividend yield of 0.26%. West Pharmaceutical Services’s dividend payout ratio is presently 12.46%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on WST shares. Bank of America upped their target price on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. UBS Group upgraded West Pharmaceutical Services from a “neutral” rating to a “buy” rating and increased their price objective for the company from $350.00 to $390.00 in a research note on Thursday, December 12th. Wolfe Research started coverage on West Pharmaceutical Services in a research report on Friday, December 13th. They issued a “peer perform” rating on the stock. StockNews.com raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Citigroup started coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 8th. They issued a “buy” rating and a $400.00 price objective on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $403.75.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.